Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer


Gastric & Breast Cancer e-journal

DOI: 10.2122/gbc.2008.0084


EDITORIAL

Bevacizumab for metastatic breast cancer – Promise and Concerns

Dimitrios H. Roukos, M.D

Abstract:

Since there is no abstract, we provide the first paragraph

 

Antiangiogenic therapy for cancer represents a major hope of current research. Given the dependence of tumor growth and metastasis on blood vessels, agents that block the development on new blood vessels (neo-angiogenesis) might be effective in improving outcome of cancer patients. Nevertheless, nearly three decades after the first publication of the concept that angiogenesis is a rational target for therapy and successful preclinical research [1], there are still challenges in integrating anti-angiogenesis therapy into clinical practice [2, 3].

 

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 3 February 2004